Back to Search Start Over

Axonal-Variant Guillian-Barre Syndrome Temporally Associated With mRNA-Based Moderna SARS-CoV-2 Vaccine.

Axonal-Variant Guillian-Barre Syndrome Temporally Associated With mRNA-Based Moderna SARS-CoV-2 Vaccine.

Authors :
Dalwadi V
Hancock D
Ballout AA
Geraci A
Source :
Cureus [Cureus] 2021 Sep 26; Vol. 13 (9), pp. e18291. Date of Electronic Publication: 2021 Sep 26 (Print Publication: 2021).
Publication Year :
2021

Abstract

We present a case of an 86-year-old woman who presented with a progressive quadriparesis two days after her second dose of Moderna SARS-CoV-2 vaccine, with cerebrospinal fluid (CSF) evidence of cytoalbuminocytological dissociation and electromyogram/nerve conduction studies (EMG/NCS) findings suggestive of acute axonal motor neuropathy. Her clinical symptoms did not improve with plasmapheresis. There appears to be a potential temporal association between the inoculation of mRNA-based SARS-CoV-2 vaccines and the development of Guillain-Barre Syndrome (GBS). Despite this possible association, infection prevention using highly effective mRNA-based vaccines remains highly recommended. Large epidemiological studies of SARS-CoV-2 vaccine-related adverse events are needed. Physicians should be aware of this possible temporal association since the prompt diagnosis and treatment of GBS can drastically improve outcomes. The aim is to report a case of axonal-variant GBS that was temporally associated with an mRNA-based SARS-CoV-2 vaccine.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright © 2021, Dalwadi et al.)

Details

Language :
English
ISSN :
2168-8184
Volume :
13
Issue :
9
Database :
MEDLINE
Journal :
Cureus
Publication Type :
Academic Journal
Accession number :
34722067
Full Text :
https://doi.org/10.7759/cureus.18291